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OBJECTIVE—ob/ob and db/db mice manifest myocardial hyper-
trophy, insulin resistance, altered substrate utilization, mitochon-
drial dysfunction, and lipid accumulation. This study was designed
to determine the contribution of central and peripheral leptin sig-
naling to myocardial metabolism and function in ob/ob and db/db
mice in the absence of diabetes and morbid obesity.
RESEARCH DESIGN AND METHODS—Male ob/ob mice
(aged 4 weeks) were caloric restricted by pairfeeding to a leptin-
treated ob/ob group. In addition to determining glucose toler-
ance and circulating lipid concentrations, myocardial substrate
metabolism and mitochondrial function were determined in
saponin-permeabilized cardiac ﬁbers. Second, experiments were
performed to determine whether leptin treatment by intraperito-
neal injection or intracerebroventricular infusion could normalize
myocardial palmitate oxidation in caloric-restricted ob/ob mouse
hearts.
RESULTS—Despite normalizing body weight and glucose toler-
ance, fat mass and circulating lipid levels remained increased in
caloric-restricted ob/ob animals. Palmitate oxidation remained
elevated in caloric-restricted ob/ob hearts and was normalized
by intraperitoneal or intracerebroventricular leptin. Intraperito-
neal and intracerebroventricular treatment also normalized cir-
culating free fatty acid levels, myocardial fatty acid oxidation
gene expression, and myocardial insulin sensitivity.
CONCLUSIONS—These data suggest that impaired hypotha-
lamic leptin signaling is sufﬁcient to increase myocardial fatty
acid oxidation by increasing delivery of free fatty acid substrates
and peroxisome proliferator–activated receptor-a ligands to the
heart. Diabetes 60:1424–1434, 2011
L
eptin is an adipocyte-secreted hormone that acts
at the level of the hypothalamus to decrease ap-
petite and increase energy expenditure (1). Leptin
also increases fatty acid oxidation (FAO) rates in
peripheral tissues by central and peripheral signaling via
leptin receptors (Ob-Rs) (2). Previous studies have sug-
gested that leptin may directly inﬂuence myocardial metab-
olism and function (2–7). Incubation of cultured neonatal
cardiomyocytes with leptin leads to cellular hypertrophy,
suggesting that leptin is prohypertrophic in vitro, but one
study has suggested an antihypertrophic effect of leptin
in vivo (3,6,7). Leptin is cardioprotective in ischemia/
reperfusion injury and activates the cardioprotective Akt
and mitogen-activated protein kinase (MAPK) pathways
(8). Chronic leptin administration increases heart rate in
mouse and rat models, and serum leptin levels are posi-
tively correlated with heart rate in modestly obese and
hypertensive subjects (9,10). These observations support
a putative role for leptin signaling in the heart in vivo and
suggest that hyperleptinemia and leptin resistance might
independently impact heart function. However, the con-
sequences of impaired leptin action, both centrally and
peripherally, on myocardial function and metabolism in
vivo remain incompletely understood.
A widely studied genetic model of leptin deﬁciency is
the ob/ob mouse, which develops morbid obesity and the
characteristic hyperinsulinemia and hyperglycemia of type 2
diabetes by 8 weeks of age (4,11). ob/ob hearts exhibit
functional and metabolic defects, including cardiac hyper-
trophy, insulin resistance, increased palmitate oxidation,
and reduced cardiac power and efﬁciency, which precede
the development of diabetes (11). Similar changes have
been described in db/db mice (11). In db/db mice, periph-
eral leptin signaling via the short forms of the leptin re-
ceptor is presumably intact, but they lack the long form of
the leptin receptor in the hypothalamus as well as in the
periphery (12–14). Circulating leptin levels are elevated in
db/db mice, reﬂecting severe leptin resistance (15). In both
of these models, it is unclear which of the well-described
cardiac defects are caused by leptin deﬁciency, versus ef-
fects that are secondary to obesity and type 2 diabetes.
Previous reports have shown that a signiﬁcant reduction
in caloric intake below that of wild-type mice is sufﬁcient
to normalize body weight and glucose tolerance in ob/ob
mice (16–19). Therefore, we used a pairfeeding model of
caloric restriction to evaluate the consequences of leptin
deﬁciency on myocardial metabolism and function in vivo
by minimizing the confounding effects of obesity and hy-
perglycemia. We hypothesized that leptin deﬁciency con-
tributed to the myocardial metabolism in ob/ob mice via
mechanisms that are independent of obesity, insulin re-
sistance, and hyperglycemia. If true, hearts from caloric-
restricted ob/ob mice should reveal persistent metabolic
and functional abnormalities despite normalization of
body weight. Because our goal was to elucidate the impact
of leptin deﬁciency in the absence of obesity we elected to
pairfeed young (aged 4 weeks) ob/ob mice before the onset
of morbid obesity. Palmitate oxidation remained elevated
in caloric-restricted ob/ob hearts under basal and insulin-
perfused conditions and central leptin infusion was sufﬁ-
cient to normalize myocardial FAO, circulating free fatty
acid (FFA) levels, and myocardial FAO gene expression in
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ORIGINAL ARTICLEcaloric-restricted ob/ob mice. Together, these results sug-
gest that central leptin signaling regulates myocardial FAO
in part by regulating the delivery of fatty acids (FA) and
PPAR-a ligands to the heart.
RESEARCH DESIGN AND METHODS
Animals. The Institutional Animal Care and Use Committee at the University of
Utah approved these studies. Male (aged 4 to 5 weeks), ob/ob, db/db, and wild-
type mice were purchased from The Jackson Laboratory (Bar Harbor, ME).
Mice were singly housed in temperature-controlled facilities operating on a
12-h:12-h light/dark cycle and were random fed standard chow (24.53% pro-
tein, 4.38% fat; Teklad 8656, Madison, WI) or were caloric restricted according
to the protocol discussed below. All mice had access to water ad libitum.
Caloric restriction: pairfeeding studies. ob/ob mice were treated with
leptin (National Hormone and Peptide Program, Dr. A.F. Parlow, Torrance,
CA) twice daily (1 mg/kg at 9:00 A.M. and 2 mg/kg at 6:00 P.M.). A set of 4-week-
old male ob/ob mice was fed the amount of food that the leptin-treated ob/ob
group consumed the previous day. These pairfed mice were given half of their
daily food at the 9:00 A.M. and 6:00 P.M. treatment times and are designated ob/ob
CR (caloric restriction). Other control groups included: random-fed ob/ob
mice, leptin-treated/random-fed wild-type mice, and random-fed wild-type
mice. All nonleptin-treated mice received vehicle injections of PBS (pH 7.8).
Caloric-restricted db/db mice were also fed an isocaloric diet matching that of
the leptin-treated ob/ob mice. Mouse weights and food intake were measured
daily. Treatments continued for 3 weeks. This duration of caloric restriction was
based on body weight and glucose tolerance responses of caloric-restricted
ob/ob mice. Our preliminary data suggested that 2 weeks of caloric restriction
was sufﬁcient to normalize glucose tolerance and body weight, although serum
insulin levels remain elevated. Body weight and glucose tolerance were not
changed further during the 3rd week of treatment, and there was no further
reduction in serum insulin levels. Thus a 3-week time point was used for all
studies given that body weights and glucose tolerance had been normalized
and remained stable for an additional 7 days. For intraperitoneal and in-
tracerebroventricular studies, 5-week-old ob/ob mice were used for these
studies since 4-week-old mice subsequently became unavailable from The
Jackson Laboratory. Mice were caloric restricted to 2.5 g/day or random fed for
3 weeks as described above. Mice were then treated with intraperitoneal leptin
(3 mg/kg/day, as described above) or intracerebroventricular leptin infusion
(15 ng/h) by osmotic minipump as described under intracerebroventricular
protocol while continuing caloric restriction. Controls received vehicle, i.e., PBS
(pH 7.8). Treatment continued for 1 week, after which the mice were killed.
Intracerebroventricular protocol. Leptin or saline was administered using
the Alzet Brain Infusion Kit 3 and micro-osmotic pump (1007D; DURECT,
Cupertino, CA). Mice were anesthetized with chloral hydrate (400 mg/kg) and
secured to a stereotactic apparatus adapted for mouse use (David Kopf
Instruments, Tujunga, CA). The cannula was placed according to the stereo-
tactic coordinates (A/P: 20.8 mm; M/L: 20.7 mm; D/V: 22.5 mm) and secured
with Loctite 454 superglue (Loctite, Düsseldorf, Germany). Osmotic mini-
pumps were implanted subcutaneously in the scapular region and connected
to the cannula via Tygon S-54-HL tubing (Saint-Gobain Performance Plastics,
Paris, France). The incision was sutured, and the mouse was placed on a 37°
plate until conscious. The animals were treated with buprenorphrine hydro-
chloride (0.05 mg/kg) for 2 days after surgery.
Glucose tolerance tests. Glucose tolerance tests (GTTs) were performed as
previously described (20). Brieﬂy, mice were injected with an intraperitoneal
injection of glucose (1 mg/g) after 6 h of fasting. Blood glucose levels were
measured using a standard glucometer (Bayer, Elkhart, IN). Blood was
obtained from the tail vein for insulin measurements before and 30 min after
intraperitoneal glucose injection in an Eppendorf tube containing a small ball
of Teﬂon. The serum was removed and used to measure insulin levels using
a sensitive rat insulin RIA kit (Linco, St. Charles, MO).
Serum fatty acids, triglyceride, adiponectin, and leptin levels. Mice were
fasted for6 h,and blood was collected from the submandibular vein. The serum
was collected as described above, and circulating triglycerides and FFA
concentrations were determined using kits from Wako Diagnostics (Richmond,
VA). Serum adiponectin and leptin were measured using speciﬁcr a d i o i m m u n o -
assay kits (Linco).
Working hearts. Hearts were excised and perfused in the working mode with
Krebs-Henseleit buffer (KHB) containing 0.4 mM palmitate bound to 3% BSA
and 5 mmol/L glucose at 37°C with or without 1 nmol/L insulin as previously
described (4,11). The buffer was gassed with 95% O2 and 5% CO2. Palmitate
oxidation rates were determined by measuring the amount of
3H2O released
from [9–10–3H] palmitate during 60 min of perfusion.
Mitochondrial respirations. Hearts were perfused via retrograde perfusion
for 20 min with KHB as previously described (21). The buffer contained 1 mM
palmitate preabsorbed to 3% BSA and 11 mmol/L glucose to mimic the diabetic
milieu of ob/ob mice. Fibers were separated from the inner left ventricle and
permeabilized as previously described (22). Oxygen consumption was mea-
sured at 25°C in KCl buffer supplemented with 20 mmol/L palmitoyl-carnitine
and then subsequently with ADP, cytochrome C, or oligomycin. Respiration
rates were normalized to dry ﬁber weight.
Electron microscopy. Samples were removed from the inner left ventricle
after Langendorff perfusion. They were ﬁxed in 2.5% glutaraldehyde with 1%
paraformaldehyde. They were postﬁxed in 2% osmium and embedded in resin
as previously described (22).
Myocardial triglycerides. Cardiac tissue was homogenized in 1 mL of 8:1 vol/
vol chloroform/methanol. The tubes were rocked at room temperature for 3 h.
H2SO4 (800 mL) was added to each tube and centrifuged at 218 g for 10 min. A
sample (50 mL) was removed from the bottom (organic) layer and dried in
a speedvac. Triglyceride assay buffer (300 mL; Sigma-Aldrich, St. Louis, MO)
was added to each sample and incubated at 37° for 15 min with occasional
mixing. Samples were loaded onto a 96-well plate and read at 562 nm. Glycerol
was used to generate the standard curve (Sigma-Aldrich).
RNA extraction and quantitative PCR. Heart tissue was obtained from
hearts perfused in the working heart mode without insulin stimulation. The
tissue was powdered and homogenized in TRIzol reagent (Invitrogen, Carlsbad,
CA). RNA was extracted using manufacturer’s protocols. cDNA was synthesized
from equivalent amounts of RNA using Superscript III Reverse Transcriptase
(Invitrogen) and oligo dT primers. Quantitative (q)PCR products were nor-
malized to the 16S ribosomal subunit gene and expressed as fold change from
controls.
Statistics.Allstatisticswereperformedbyone-wayANOVAusingtheStatview
5.0.1 software (SAS Institute, Cary, NC). Statistical signiﬁcance was accepted
when the P value was less than 0.05.
RESULTS
Food intake, body composition, and systemic metab-
olism in caloric-restricted ob/ob and db/db mice.
Random-fed ob/ob mice consumed signiﬁcantly more food
than wild-type controls, whereas leptin treatment signiﬁ-
cantly lowered food consumption below wild-type levels.
Caloric-restricted ob/ob mice were fed an isocaloric diet to
that of the leptin-treated ob/ob mice (Fig. 1A). Weight gain
was accelerated in random-fed ob/ob mice compared with
wild-type controls. Leptin treatment reduced body weight in
wild-type mice and normalized body weight in ob/ob mice.
Caloric restriction normalized body weight in ob/ob mice
(Fig. 1B). Body composition was not normalized in caloric-
restricted ob/ob mice despite normalization of body weight.
Fat pad mass was signiﬁcantly increased in random-fed and
caloric-restricted ob/ob mice in comparison with wild-type
mice, whereas leptin treatment restored fat mass to wild-
type levels (Fig. 1C and D). Altered body composition in
caloric-restricted ob/ob mice correlated with a decrease in
oxygen consumption, heat production, and uncoupling
protein-1 (UCP-1) content in brown adipose tissue (BAT)
depots, despite an increase in movement (Supplementary
Fig. 1).
Glucose tolerance was signiﬁcantly impaired in random-
fed ob/ob mice when compared with wild-type controls.
Leptin treatment normalized glucose tolerance in ob/ob
mice, as did caloric restriction of ob/ob mice. Despite
normalization of glucose tolerance, caloric restriction re-
duced fasting insulin concentrations in ob/ob mice by
;50%, so that they remained two- to threefold higher than
random-fed wild-type controls. Leptin treatment normal-
ized insulin concentrations in ob/ob mice, by returning
them to the levels observed in random-fed wild-type mice
(Fig. 1E and F).
Circulating FFA concentrations were elevated in random-
fed ob/ob mice, when compared with wild-type controls
(Table 1). Triglyceride concentrations were not signiﬁcantly
elevated in random-fed ob/ob mice. FFA and triglyceride
concentrations were further increased in caloric-restricted
ob/ob mice (Tables 1 and 3) but were reduced by leptin
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adiponectin concentrations in random-fed ob/ob mice were
comparable with random-fed wild-type mice, as were adipo-
nectin levels in leptin-treated ob/ob mice. Adiponectin con-
centrations in caloric-restricted ob/ob mice were increased
threefold to that of random-fed wild-type levels. Leptin was
not detectable in untreated ob/ob mice, and leptin concen-
trations in leptin-treated ob/ob and wild-type mice were not
signiﬁcantly different than random-fed wild-type levels after
6ho ff a s t i n g .
To determine whether similar changes in body compo-
sition and metabolism would occur in a model of leptin
resistance, we applied the same degree and duration of
caloric restriction to 4-week-old db/db mice. Adipose tissue
weight and circulating insulin concentrations remained
elevated in caloric-restricted db/db mice, despite normali-
zation of body weight and glucose tolerance (Fig. 2).
Myocardial function and FAO in ob/ob and db/db
mice. We performed isolated working heart perfusions
to determine whether myocardial metabolism was altered
in caloric-restricted ob/ob mice (Fig. 3A). Palmitate oxi-
dation was elevated in random-fed ob/ob hearts when
perfused with insulin. Leptin treatment restored insulin
responsiveness in the hearts of ob/ob mice. Palmitate oxi-
dation rates were increased in caloric-restricted ob/ob
hearts when compared with random-fed wild-type hearts.
FIG. 1. Altered body composition but normal glucose tolerance in caloric-restricted (CR) ob/ob mice. Average daily food intake (A), body weight
(B), body composition (C), and adipose tissue weight (D)o fob/ob mice are shown. E: GTT performed on mice during 3rd week of treatment after
6 h of fasting. F: Serum insulin levels collected before and 30 min after glucose injection. Numbers of animals are shown in each ﬁgure. RF, random
fed.
aP < 0.05 vs. wt RF saline;
bP < 0.05 vs. ob/ob RF saline;
cP < 0.05 vs. ob/ob CR saline; *P < 0.05 vs. basal conditions of same treatment group.
DEXA, dual-energy X-ray absorptiometry; RF, random fed; wt, wild type.
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restricted ob/ob hearts, palmitate oxidation remained higher
than rates observed in insulin-perfused, random-fed wild-
type hearts. Similar ﬁndings were observed in random-fed
and caloric-restricted db/db hearts, which showed higher
palmitate oxidation and lower glucose oxidation when
compared with random-fed wild-type controls (Fig. 3B and
Supplementary Fig. 2). We measured dry heart weights
postperfusion to determine the impact of caloric restric-
tion on cardiac hypertrophy in ob/ob and db/db hearts.
Heart weights from random-fed ob/ob mice but not db/db
mice were increased when compared with random-fed
wild-type hearts. Leptin treatment and caloric restriction
normalized heart weights to levels similar to that of ran-
dom-fed wild-type mice (Table 2).
Mitochondrial function in caloric-restricted ob/ob
mouse hearts. We previously reported that mitochon-
dria from ob/ob mice were uncoupled after perfusion with
FA (21). Thus we sought to determine whether mitochon-
dria of caloric-restricted ob/ob mice remained uncoupled
when hearts were perfused with palmitate before mito-
chondrial studies. We only performed these studies in
ob/ob mice, since similar changes in systemic and myo-
cardial metabolism were observed in both ob/ob and db/db
mice. Oxygen consumption rates in saponin-permeabilized
ﬁbers exposed to palmitoyl carnitine were similar in all
groups (Fig. 3C). However ATP production rates trended
lower in ﬁbers isolated from both random-fed and caloric-
restricted ob/ob mice (Fig. 3D) resulting in signiﬁcantly
lower ATP/O ratios. Thus mitochondria from caloric-
restricted ob/ob mice remained uncoupled despite normali-
zation of body weight. This contrasts with normalization of
mitochondrial coupling in leptin-treated ob/ob mouse hearts.
Transmission electron microscopy was performed to
determine whether leptin treatment or caloric restriction
modiﬁed mitochondrial morphology (Fig. 3F). Although
major changes in mitochondrial morphology between
groups were not observed, striking differences in lipid
droplet accumulation were noted. Leptin treatment re-
versed myocardial lipid droplet accumulation. In contrast,
the number of lipid droplets in hearts from caloric-restricted
ob/ob mice was similar to those observed in random-fed
ob/ob animals. To quantify these microscopic features, we
measured myocardial triglyceride content. There was a
signiﬁcant elevation in myocardial triglyceride levels in
random-fed ob/ob mice relative to wild-types (Fig. 3E) and
normal levels in leptin-treated ob/ob hearts. Triglyceride
levels were not signiﬁcantly reduced in caloric-restricted
ob/ob hearts compared with random-fed ob/ob mice, nor
were they signiﬁcantly elevated when compared with wild-
type mice, indicating an intermediate degree of myocardial
triglyceride accumulation.
Systemic metabolic milieu of caloric-restricted mice
after intracerebroventricular or peripheral leptin
treatment. The experiments described thus far do not
distinguish whether the altered myocardial FAO observed
in caloric-restricted ob/ob mice was a result of caloric re-
striction or leptin deﬁciency per se. Moreover, studies in
caloric-restricted db/db mice suggested that hypothalamic
leptin signaling via the Ob-Rb isoform of the leptin re-
ceptor is important in maintaining normal myocardial
metabolism in caloric-restricted mice. Therefore, we per-
formed two studies in which caloric-restricted wild-type
and ob/ob mice were treated with intraperitoneal or intra-
cerebroventricular leptin to determine whether systemic
or central leptin can normalize myocardial metabolism.
Male mice (aged 5 weeks) were obtained from The Jackson
Laboratory and random fed or caloric restricted (2.5 g/day)
for 3 weeks. Mice were then treated with systemic (in-
traperitoneal study; 3 mg/kg/day) or intracerebroventricular
study (15 ng/h) leptin for 1 week. Mice were caloric re-
stricted throughout the 4-week protocol. At the conclusion of
the study, body weights of caloric-restricted mice were
mildly elevated relative to wild-type controls (Supplementary
Fig. 3A–D). Leptin treatment by intraperitoneal injection
reduced body weight and adipose mass in caloric-restricted
ob/ob mice (Fig. 4A). Caloric-restricted wild-type mice
weighed signiﬁcantly less than controls, and white adipose
tissue mass was signiﬁcantly reduced by leptin treatment.
Intracerebroventricular infusion of leptin reduced body
weight and white adipose tissue mass in caloric-restricted
ob/ob mice (Fig. 4B). However, this reduction was not
equivalent to the reduction observed in the intraperitoneal-
treated mice. In contrast, intraperitoneal and intra-
cerebroventricular leptin treatment were sufﬁcient to
normalize BAT weight in caloric-restricted ob/ob mice.
Gastrocnemius weight was also increased by intraperito-
neal and intracerebroventricular leptin treatment, suggest-
ing that fat mass was spared at the expense of muscle mass
in caloric-restricted ob/ob mice (Fig. 4C and D).
We measured circulating lipid and hormone levels to
determine whether 1 week of leptin treatment via intra-
peritoneal or intracerebroventricular routes was sufﬁcient
to normalize systemic metabolism in caloric-restricted
ob/ob mice (Table 3). Serum FFA levels were signiﬁcantly
increased by caloric restriction in ob/ob but not wild-type
TABLE 1
Circulating lipid and hormone concentrations
FFAs (mM) Triglycerides (mg/dL) Adiponectin (mg/mL) Leptin (ng/mL)
Pairfeeding studies
Wt RF saline 0.6 6 0.1 (14) 21.3 6 3.0 (21) 6.4 6 1.0 (9) 0.8 6 0.2 (8)
Wt RF leptin 0.6 6 0.1
c (11) 15.9 6 2.8
b,c (21) 6.4 6 0.6
c (10) 1.2 6 0.2 (6)
ob/ob RF saline 0.9 6 0.2
a (11) 30.8 6 4.7 (11) 8.7 6 0.9 (11) ND (6)
ob/ob RF leptin 0.7 6 0.1
c (11) 20.9 6 2.2
c (16) 6.9 6 0.8
c (11) 1.4 6 0.3 (5)
ob/ob CR saline 1.1 6 0.2
a (8) 41.4 6 5.3
a (10) 17.4 6 1.3
a,b (15) ND (5)
db/db CR studies
Wt RF 0.7 6 0.1 (8) 21.3 6 2.7 (13) 5.6 6 0.8 (6) 0.8 6 0.4 (7)
db/db RF 1.5 6 0.1
a (4) 42.6 6 10.7
a (7) 8.9 6 0.6 (7) 63.8 6 1.1
a (4)
db/db CR 1.4 6 0.1
a (6) 34.6 6 2. (11) 14.6 6 1.8a,b (10) 17.6 6 1.2
a,b (4)
Circulating concentrations of FFAs, triglycerides, adiponectin, and leptin were measured after 6 h of fasting (number of animals is indicated in
parentheses).
aP , 0.05 vs. wt RF saline;
bP , 0.05 vs. ob/ob RF saline or db/db RF;
cP , 0.05 vs. ob/ob CR saline. ND, not detected; RF, random fed;
wt, wild type.
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cerebroventricular leptin treatment. Caloric restriction in-
creased serum adiponectin levels in wild-type and ob/ob
mice. Intracerebroventricular leptin treatment did not in-
crease circulating leptin levels. Surprisingly, adiponectin
levels were further increased in caloric-restricted ob/ob
mice treated with intracerebroventricular leptin. Caloric
restriction or leptin treatment by intraperitoneal injection
or intracerebroventricular infusion improved glucose tol-
erance in ob/ob mice and signiﬁcantly lowered glucose
levels in caloric-restricted wild-type mice (Fig. 4E–H). Insulin
levels were also reduced by intraperitoneal and intra-
cerebroventricular leptin under basal and glucose-stimulated
conditions.
Myocardial FAO in caloric-restricted mice after cen-
tral or peripheral leptin repletion. To determine whether
myocardial FAO was normalized by leptin repletion, we
performed isolated working heart perfusions on caloric-
restricted ob/ob and wild-type mice treated with intraperi-
toneal and intracerebroventricular leptin (Fig. 5A and B).
Myocardial FAO was increased in caloric-restricted ob/ob
hearts as previously observed, but myocardial FAO was not
changed in caloric-restricted wild-type hearts. Furthermore,
FAO remained elevated in random-fed and caloric-restricted
ob/ob mice under insulin-perfused conditions. Intraperi-
toneal and intracerebroventricular leptin treatment re-
duced basal and insulin-perfused FAO in caloric-restricted
ob/ob hearts and further repressed myocardial FAO in
FIG. 2. Altered body composition but normal glucose tolerance in caloric-restricted db/db mice. Average daily food intake (A), body weight (B),
body composition (C), and adipose tissue weight (D)o fdb/db mice are shown. E: GTT performed on mice during 3rd week of treatment after 6 h of
fasting. F: Serum insulin levels collected before and 30 min after glucose injection. Numbers of animals are shown in each ﬁgure.
aP < 0.05 vs. wt
RF;
bP < 0.05 vs. db/db RF; *P < 0.05 vs. basal conditions of same treatment group. RF, random fed; wt, wild type.
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1428 DIABETES, VOL. 60, MAY 2011 diabetes.diabetesjournals.orgFIG. 3. Increased triglyceride content and mitochondrial uncoupling accompany elevated myocardial palmitate oxidation in caloric-restricted
mouse hearts. Myocardial palmitate oxidation as measured by isolated working heart perfusion in ob/ob (A)a n ddb/db mice (B). C: Mitochondrial
respirations from saponin-permeabilized ﬁbers isolated from ob/ob hearts. V0, basal respiration; VADP, maximal ADP-stimulated respiration; Voligo,
oxygen consumption in the presence of oligomycin; RC, respiratory control ratio (VADP/Voligo). D: ATP production rate and ATP/state 3 respira-
tions (ATP/O ratio) for saponin-permeabilized ﬁbers. E: Myocardial triglyceride content. F: Transmission electron microscopy of myocardial tissue
from inner left ventricle. Magniﬁcation 32,000 (top row) and 38,000 (bottom row). Arrows indicate lipid droplets.
aP < 0.05 vs. wt RF saline;
bP <
0.05 vs. ob/ob RF or db/db RF;
cP < 0.05 vs. ob/ob CR saline; *P < 0.05 vs. basal conditions of same treatment group. dfw, dry ﬁber weight; dhw, dry
heart weight; dw, dry weight; RF, random fed; wt, wild type.
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phosphorylation in these hearts to determine whether in-
sulin sensitivity was altered by caloric restriction. Random-
fed and caloric-restricted ob/ob mice were insulin resistant
at the level of Akt and S6 phosphorylation. Intraperitoneal
and intracerebroventricular leptin treatment normalized
insulin-stimulated Akt and S6 phosphorylation in caloric-
restricted ob/ob mice (Supplementary Fig. 4).
Transcript levels of FAO regulatory genes were mea-
sured to determine whether myocardial FAO in caloric-
restricted ob/ob mice was elevated as a result of increased
FAO capacity (Fig. 5C and D). FAO gene expression
was increased in the hearts of random-fed and caloric-
restricted ob/ob mice. These genes include the PPAR-a
targets: medium and long chain acyl CoA dehydrogenases,
the FA transporter CD36, and Hadha /Hadhb, the subunits
of the mitochondrial trifunctional protein. These increases
were not observed in caloric-restricted wild-type mice.
Myocardial FAO gene expression was normalized by in-
traperitoneal and intracerebroventricular leptin in caloric-
restricted ob/ob mouse hearts. Furthermore, intraperitoneal
and intracerebroventricular leptin tended to reduce FAO
gene expression in caloric-restricted wild-type mice. No
signiﬁcant changes were observed in PPAR-a, PPARg
coactivator-1a, malonyl CoA decarboxylase (MCD), UCP-2,
or UCP-3 expression levels (data not shown).
DISCUSSION
Intraperitoneal and intracerebroventricular leptin
normalize myocardial FAO potentially by normalizing
FFA delivery to the heart and reducing myocardial
FAO capacity. The main ﬁndings of this study are that
metabolic abnormalities that characterize the heart in
ob/ob and db/db mice, which are commonly used to model
the cardiomyopathy of obesity and diabetes, are not re-
versed by caloric restriction, despite normalization of
glucose tolerance and body weight. Speciﬁcally, in caloric-
restricted ob/ob and db/db mice these changes occur in
parallel with increasing circulating concentrations of FFA
and triglycerides and modest hyperinsulinemia. Repletion of
leptin both systemically and directly to the central nervous
system (intracerebroventricular) normalized circulating FFA
and triglyceride concentrations and expression levels of
PPAR-a target genes that regulate FAO capacity in the
heart, in concert with normalization of myocardial me-
tabolism and mitochondrial function. Abnormalities in
myocardial FAO in ob/ob and db/db mice are multifactorial,
reﬂecting consequences of hyperglycemia, hyperinsulinemia,
and increased myocardial lipid delivery. However, the ma-
jor impact of leptin repletion in caloric-restricted ob/ob mice
appears to be repression of FAO gene expression, which we
propose is the result of reduced delivery of FA, which are
PPAR-a ligands, to the heart. Moreover, hyperinsulinemia
might promote increased FA utilization in the heart by
increasing CD36 translocation (23), and normalization of
circulating insulin concentrations would reverse this.
Given the impact of leptin to lower FAO rates and FAO
gene expression in caloric-restricted wild-type mice, the
possibility remains that leptin might also directly regulate
myocardial FAO capacity independently of circulating FA
and insulin concentrations. Although we did not directly
measure glucose utilization rates in this study, our prior
studies have shown that in hearts perfused with glucose
and palmitate, lowering of FA utilization by decreasing FA
concentrations or by perfusing hearts with insulin is as-
sociated with an increase in glucose utilization (4). Thus
we expect that the normalization of FA utilization in
caloric-restricted ob/ob mice by leptin will increase myo-
cardial glucose utilization.
The current study also raises the intriguing possibility
that leptin may regulate mitochondrial coupling in the
heart. We previously reported that mitochondrial uncou-
pling developed in hearts from ob/ob and db/db mice after
exposure of these hearts to FA (21,22,24). We conﬁrmed
these ﬁndings in the current study, but now also show that
mitochondrial uncoupling persists in caloric-restricted
ob/ob mice in which glucose tolerance is normalized. In
contrast, leptin treatment, which also normalized glucose
tolerance and circulating FFA levels, restored coupled
mitochondrial respiration. Although the mechanisms re-
sponsible for persistent mitochondrial dysfunction in hearts
from caloric-restricted ob/ob mice remain to be elucidated,
our observations are consistent with a role for persistent
myocardial FA delivery in contributing to mitochondrial
uncoupling in these hearts. Taken together, the current
study underscores potential mechanisms by which im-
paired hypothalamic leptin signaling may contribute to
altered myocardial substrate metabolism and mitochon-
drial function in obesity and diabetes. Given that leptin
resistance is a uniform characteristic of individuals with
acquired obesity (25), our studies raise the possibility that
impaired central leptin action may contribute to altered
cardiac metabolism and mitochondrial function in these
individuals.
Caloric restriction further increased circulating con-
centrations of FFA and triglycerides in ob/ob mice, and fat
pad weight was increased at the expense of lean mass,
conﬁrming previous reports that caloric-restricted ob/ob
mice retain features of insulin resistance, characterized by
increased adiposity (16–19). Thus leptin deﬁciency pro-
motes myocardial FA utilization by increasing FA substrate
availability. The lipolytic response to caloric restriction in
ob/ob mice resembles an exaggerated fasting response,
which under physiological circumstances is driven in part
by reduced adipocyte insulin signaling coupled with stim-
ulation of lipolysis by counterregulatory hormones. Thus
although insulin levels in caloric-restricted ob/ob mice re-
main elevated, our observations suggest that adipose tissue
TABLE 2
Heart weights in caloric-restricted ob/ob and db/db mice
with leptin treatment
Treatment
group
DHW
(mg)
Tibia length
(mm)
DHW/Tibia
length (mg/mm)
Wt RF
saline (25) 20.4 6 0.7 15.6 6 0.1 1.3 6 4.3 E-05
Wt RF
leptin (22) 18.1 6 0.9
a,b 15.6 6 0.1
b 1.2 6 5.4 E-05
a,b
ob/ob RF
saline (19) 25.1 6 0.7
a 14.7 6 0.1
a 1.7 6 4.2 E-05
a
ob/ob RF
leptin (21) 21.4 6 0.6
b 15.6 6 0.1
b 1.4 6 3.5 E-05
b
ob/ob CR
saline (28) 19.4 6 0.6
b 14.5 6 0.2
a 1.3 6 3.7 E-05
b
Wt RF (6) 22.4 6 0.6 16.7 6 0.2 1.4 6 0.05
db/db RF (8) 23.3 6 0.9 15.2 6 0.2
a 1.5 6 0.08
db/db CR (8) 19.0 6 0.4
a,b 14.7 6 0.2
a,b 1.3 6 0.02
b
Dry heart weights (DHW) obtained after working heart perfusions in
9-week-old male mice with 1 week of intraperitoneal or intracerebro-
ventricular leptin are shown.
aP , 0.05 vs. wt RF saline;
bP , 0.05 vs.
ob/ob RF saline or db/db RF. RF, random fed; wt, wild type.
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1430 DIABETES, VOL. 60, MAY 2011 diabetes.diabetesjournals.orgFIG. 4. Intraperitoneal and intracerebroventricular leptin are sufﬁcient to alter body composition and serum insulin levels. Adipose tissue and
gastrocnemius muscle weights in mice treated with intraperitoneal (A, C) or intracerebroventricular (B, D) leptin for 1 week are shown. GTTs
(E, F) and serum insulin levels (G, H) before and 30 min after glucose injection are shown. Numbers of animals are indicated in each ﬁgure. For
intraperitoneal leptin study,
aP < 0.05 vs. wt RF;
bP < 0.05 vs. ob/ob RF;
cP < 0.05 vs. ob/ob CR. For intracerebroventricular leptin study,
aP < 0.05
vs. wt CR intracerebroventricular saline;
cP < 0.05 vs. ob/ob CR intracerebroventricular saline. icv, intracerebroventricular; L 1 wk, 1 week of
leptin treatment; RF, random fed; wt, wild type.
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and that this is reversed by central repletion of leptin. The
mechanisms by which caloric restriction increased lipoly-
sis in ob/ob mice despite an apparent modest increase in
whole animal insulin sensitivity and normalization of glucose
tolerance are incompletely understood. Future studies
will be needed to elucidate these mechanisms by exam-
ining activities and expression levels of regulators of li-
polysis such as adipose triglyceride lipase and lipoprotein
lipase. Leptin has been suggested to increase whole
TABLE 3
Circulating lipids and hormones in caloric-restricted ob/ob mice with leptin treatment
Treatment group FFAs (mM) Triglycerides (mg/dL) Adiponectin (mg/mL) Leptin (ng/mL)
Wt RF 0.7 6 0.1 (4) 45.5 6 5.2 (3) 10.6 6 1.2 (5) 2.6 6 0.5 (4)
Wt CR 1.0 6 0.1
c (5) 43.3 6 4.8
c (7) 18.0 6 1.4
a,b,c (5) 3.0 6 0.2 (4)
Wt CR + L 1 week 0.8 6 0.2
c (4) 32.0 6 1.9
c (4) 13.8 6 1.3
c (5) 6.4 6 1.9
a (3)
ob/ob RF 0.7 6 0.1 (3) 40.5 6 2.0 (3) 10.7 6 1.4 (4) ND (3)
ob/ob CR 1.4 6 0.02
a,b (5) 57.6 6 3.6
b (5) 21.9 6 0.6
a,b (6) ND (3)
ob/ob CR + L 1 week 0.6 6 0.1
c (4) 50.5 6 2.6 (4) 17.9 6 2.0
a,b,c (4) 1.0 6 0.8 (3)
Wt CR intracerebroventricular saline 1.1 6 0.20 (5) 28.6 6 1.5 (3) 14.3 6 1.3 (4) 3.3 6 0.9 (3)
Wt CR intracerebroventricular leptin 0.1 6 0.04
a,c (6) 17.6 6 2.5
c (6) 8.6 6 1.6
a,c (5) 3.5 6 0.8 (3)
ob/ob CR intracerebroventricular saline 1.6 6 0.30
a (5) 43.8 6 3.3
a (4) 23.6 6 1.5
a (6) ND (3)
ob/ob CR intracerebroventricular leptin 0.6 6 0.05
a,c (5) 32.6 6 3.5
c (4) 37.9 6 2.0
a,c (7) ND (3)
Circulating concentrations of FFAs, triglycerides, adiponectin, and leptin were measured in intraperitoneal (L 1 week)- and intracerebroventricular-treated
mice after 6 h of fasting (number of animals is indicated in parentheses).
aP , 0.05 vs. wt RF or wt CR intracerebroventricular saline;
bP , 0.05 vs. ob/ob
RF;
cP , 0.05 vs. ob/ob CR or ob/ob CR intracerebroventricular saline. L 1 wk, 1 week of leptin treatment; ND, not detected; RF, random fed; wt, wild type.
FIG. 5. Intraperitoneal and intracerebroventricular leptin are sufﬁcient to normalize basal and insulin-stimulated palmitate oxidation in caloric-
restricted ob/ob hearts. Basal and insulin-stimulated palmitate oxidation after 1 week of intraperitoneal (A) or intracerebroventricular leptin (B).
C and D: qPCR analysis from noninsulin-stimulated perfused hearts. WT RF values are normalized to 1 and shown as the dashed line. MCAD, medium
chain acyl CoA dehydrogenase; LCAD, long chain acyl CoA dehydrogenase; CD36, CD36 antigen; HADHa, hydroxyacyl-CoA dehydrogenase a-subunit;
HADHb, hydroxyacyl-CoA dehydrogenase b-subunit. For intraperitoneal leptin study,
aP < 0.05 vs. wt RF;
bP < 0.05 vs. ob/ob RF;
cP < 0.05 vs. ob/ob CR;
*P < 0.05 vs. noninsulin-stimulated hearts from the same treatment group. For intracerebroventricular leptin study,
aP < 0.05 vs. wt CR intra-
cerebroventricular saline;
cP < 0.05 vs. ob/ob CR intracerebroventricular saline; *P < 0.05 vs. noninsulin-stimulated hearts from the same treatment
group. CR, caloric restriction; dhw, dry heart weight; icv, intracerebroventricular; L 1 wk, 1 week of leptin treatment; RF, random fed; wt, wild type.
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1 in the liver and increasing AMPK and ACC activation in the
liver and skeletal muscle (26–29). We did not observe any
changes in ACC or AMPK phosphorylation in liver, heart, or
skeletal muscle (data not shown) in our experimental par-
adigm. These differences might reﬂect the chronic nature of
leptin administration in these studies, which contrasts with
other studies that suggest that the ability of leptin to activate
AMPK in peripheral tissues is an acute response (30).
Caloric restriction reduced the respiratory exchange
ratios in ob/ob mice, which suggests that in addition to the
increase in cardiac FAO rates, whole body rates of FA
utilization were also increased. Conversely, the increase
in respiratory exchange ratios, insulin sensitivity, and re-
duction in myocardial palmitate oxidation in leptin-treated
ob/ob mice suggests an overall increase in glucose utiliza-
tion. We also hypothesized that leptin repletion reduced
FFA delivery to the heart by increasing FA utilization in
BAT. To test this hypothesis we measured UCP-1 content
in BAT and observed that intraperitoneal and intra-
cerebroventricular leptin increased UCP-1 content in BAT
from caloric-restricted ob/ob mice (Supplementary Fig. 5).
These data suggest that some of the FFAs released by li-
polysis in caloric-restricted ob/ob mice were used by BAT
thereby lowering FFA delivery to the heart upon leptin re-
pletion. Thus, although leptin may acutely increase FA utili-
zation in vivo, chronic leptin repletion predominantly
decreases the relative contribution of FA oxidation to energy
expenditure by increasing insulin sensitivity, glucose utiliza-
tion, and heat production in caloric-restricted ob/ob mice.
In earlier studies, we observed that myocardial insulin
resistance in ob/ob mice occurred at the level of phos-
phoinositide 3-kinase activation despite increased tyrosine
phosphorylation of the insulin receptor (4). Leptin re-
pletion to caloric-restricted ob/ob mice restored insulin-
mediated activation of Akt in the heart. These changes
occur independently of changes in AMPK activity or acti-
vation of mammalian target of rapamycin. Our present
study design does not allow us to determine whether these
changes are secondary to normalization of the metabolic
milieu or to direct effects of central leptin signaling on
myocardial insulin signaling. Myocardial hypertrophy was
observed in random-fed ob/ob mice, but not in caloric-
restricted ob/ob mice. An earlier study suggested that lep-
tin is antihypertrophic and that caloric restriction was not
able to reverse cardiac hypertrophy (3). However, these
observations were obtained after signiﬁcant hypertrophy
had developed in ob/ob mice. In contrast, our studies suggest
that the development of cardiac hypertrophy in ob/ob mice is
not a direct consequence of leptin deﬁciency but is likely
secondary to the hemodynamic consequences of obesity.
In conclusion, the current study demonstrates that
changes in cardiac metabolism that characterize obesity
and diabetes persist in leptin-deﬁcient mice in which
obesity and glucose intolerance is prevented by reducing
caloric intake and are likely mediated by increased FFA
delivery to the heart. These observations suggest that
leptin resistance may indirectly contribute to altered car-
diac metabolism in obesity and insulin-resistant states by
regulating the delivery of FA to the heart. Not only are
these FA metabolic substrates but they also act as ligands
for PPAR-a. Our study also suggests that hypothalamic
leptin signaling may normalize myocardial insulin resis-
tance, potentially improving glucose oxidation in caloric-
restricted ob/ob hearts and reducing the overall contribution
of FA to ATP production in the heart. These studies are
not without limitations, since they were performed before
development of overt obesity and diabetes, and it remains
to be shown that intracerebroventricular leptin is sufﬁ-
cient to normalize myocardial metabolism in older ob/ob
mice, with diabetes of longer duration. Moreover, the timing
of pairfeeding and intraperitoneal leptin injections do not
mimic the nocturnal feeding patterns or diurnal rhythms of
leptin release. Nevertheless, these observations raise the
possibility that hypothalamic leptin resistance as develops in
individuals with obesity and type 2 diabetes could contribute
to altered myocardial substrate metabolism and myocardial
insulin resistance. Enhancing hypothalamic leptin sensitivity
not only represents an important approach for promoting
weight loss and reversing obesity, but the current study
provides evidence that reversal of maladaptive patterns of
myocardial substrate utilization in obesity and insulin-
resistant states is another important consequence of in-
creasing hypothalamic leptin action. Thus future studies
should seek to determine whether increasing hypotha-
lamic leptin signaling will normalize myocardial metab-
olism in obese and insulin-resistant patients.
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